Advertisement
Screener

EXAGEN INC. (XGN) Graph

XGN Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $19.94M; Cost of revenue $7.72M; Research and development $1.43M; Selling, general and administrative $12.51M.
  • 2026-03-31: Revenue $17.31M; Cost of revenue $7.10M; Research and development $1.55M; Selling, general and administrative $12.07M.
  • 2025-12-31: Revenue $16.63M*; Cost of revenue $7.42M*; Research and development $1.76M*; Selling, general and administrative $12.42M*.
  • 2025-09-30: Revenue $17.24M; Cost of revenue $7.17M; Research and development $1.73M; Selling, general and administrative $11.45M.

Major Customers

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

XGN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Other Customer$108.00KClient Direct Bill$4.28MCommercial$10.35MGovernment1$5.21MRevenue$19.94MCost of revenue$7.72MGross profit$12.22MOperating income-$1.72MOther income, net$153.00KResearch & development$1.43MSelling, general& administrative$12.51MIncome tax$0.00Net income-$3.20M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

XGN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$19.94MRevenue$19.94MCost of revenue$7.72MGross profit$12.22MOperating income-$1.72MOther income, net$153.00KResearch & development$1.43MSelling, general& administrative$12.51MIncome tax$0.00Net income-$3.20M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$19.94M$7.72M$1.43M$12.51M$0.00-$3.20M
2026-03-31$17.31M$7.10M$1.55M$12.07M$36.00K-$3.97M
2025-12-31$16.63M*$7.42M*$1.76M*$12.42M*$13.00K*-$4.67M*
2025-09-30$17.24M$7.17M$1.73M$11.45M$1.00K-$7.09M
2025-06-30$17.20M$6.81M$1.48M$11.54M$37.00K-$4.44M
2025-03-31$15.50M$6.38M$1.28M$11.20M$0.00-$3.75M
2024-09-30$12.51M$5.53M$1.48M$10.16M$0.00-$5.03M
2024-06-30$15.06M$6.01M$1.18M$10.46M$0.00-$2.97M
2024-03-31$14.41M$5.82M$1.06M$10.54M(m)-$3.36M
2023-09-30$13.42M$5.71M$1.40M$11.38M(m)-$5.42M
2023-06-30$14.14M$5.84M$1.26M$11.95M(m)-$5.01M
2023-03-31$11.23M$5.93M$1.13M$11.88M(m)-$7.69M
2022-09-30$14.73M$6.01M$2.38M$14.15M(m)-$8.10M
2022-06-30$7.61M$6.08M$2.69M$12.90M(m)-$14.66M
2022-03-31$10.39M$5.82M$2.10M$12.15M(m)-$10.27M
2021-09-30$12.25M$5.49M$1.74M$11.53M$0.00-$7.18M
2021-06-30$12.77M$5.45M$1.89M$11.17M$0.00-$6.41M
2021-03-31$10.59M$4.71M$1.40M$10.04M$0.00-$6.21M
2020-09-30$10.78M$4.34M$1.02M$9.20M$0.00-$4.31M
2020-06-30$8.95M$3.34M$751.00K$8.28M$0.00-$3.36M
2020-03-31$9.58M$4.54M$634.00K$9.63M-$118.00K-$5.56M
2019-09-30$10.44M(m)$507.00K$7.31M$0.00-$3.14M
2019-06-30$10.47M$4.99M$590.00K$7.30M$0.00-$2.79M
2019-03-31$9.26M$4.44M$513.00K$6.18M$0.00-$2.70M
2018-09-30$8.22M$3.85M$525.00K$4.93M(m)-$1.76M
2018-06-30(m)(m)(m)(m)(m)-$2.15M
2018-03-31(m)(m)(m)(m)(m)-$2.79M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$37.25M$14.82M$2.98M$24.58M$36.00K-$7.16M
2025-06-30$32.70M$13.18M$2.77M$22.75M$37.00K-$8.19M
2024-06-30$29.48M$11.82M$2.24M$21.01M$0.00-$6.33M
2023-06-30$25.37M$11.76M$2.39M$23.84M(m)-$12.70M
2022-06-30$18.00M$11.89M$4.79M$25.05M(m)-$24.94M
2021-06-30$23.36M$10.16M$3.29M$21.21M$0.00-$12.62M
2020-06-30$18.53M$7.88M$1.39M$17.90M-$118.00K-$8.93M
2019-06-30$19.73M$9.43M$1.10M$13.48M$0.00-$5.49M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$49.94M$20.35M$4.50M$34.19M$38.00K-$15.28M
2024-09-30$41.99M$17.35M$3.72M$31.17M$0.00-$11.35M
2023-09-30$38.78M$17.47M$3.79M$35.21M(m)-$18.12M
2022-09-30$32.73M$17.91M$7.17M$39.21M(m)-$33.03M
2021-09-30$35.61M$15.65M$5.04M$32.74M$0.00-$19.80M
2020-09-30$29.31M$12.22M$2.40M$27.10M-$118.00K-$13.23M
2019-09-30$30.17M(m)$1.61M$20.79M$0.00-$8.63M
2018-09-30$22.80M$11.38M$1.59M$14.42M(m)-$6.70M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$66.58M$27.78M$6.25M$46.62M$51.00K-$19.95M
2024-12-31$55.64M$22.53M$5.38M$41.37M$12.00K-$15.12M
2023-12-31$52.55M$23.09M$4.87M$47.43M$33.00K-$23.69M
2022-12-31$45.56M$24.21M$9.88M$52.02M-$282.00K-$47.39M
2021-12-31$48.30M$20.59M$7.24M$44.54M$175.00K-$26.85M
2020-12-31$41.98M$16.56M$3.57M$37.03M-$79.00K-$16.69M
2019-12-31$40.39M$18.81M$2.18M$28.70M$25.00K-$12.04M
2018-12-31$32.44M$15.38M$2.13M$19.68M$58.00K-$8.01M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45